13F data reveals net institutional outflow of $14.4B with 859 sellers vs 605 buyers; insiders net sold ~$49K over 90 days, confirming aligned selling pressure.

Confirmation

Sustained institutional redemption and further insider selling in the next quarter will lock in the bearish case.

Invalidation Risk

A reversal would require a surge in institutional accumulation or a cluster of insider buys.

The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice and should not be used as the basis for any buy or sell decision.

Insider Trading (Form 4)

2390d confidence

unique buyers

$870K

buy value

data as of 2026-07-16

12-Month Buy/Sell Activity

Mar 25

Aug 25

BuySell

操作	內部人	職稱	交易日	金額
賣出	SCHULMAN AMY W	Director	2026-03-12	$7K
賣出	Kendrick Charles Morgan JR	EVP & President, Commercial	2026-03-06	$911K
買入	COLLIS STEVEN H	Executive Chairman	2026-03-05	$870K
買入	DeVore Susan D.	Director	2025-08-19	$375K
買入	BOUDREAUX GAIL	President and CEO	2025-07-18	$668K
買入	BOUDREAUX GAIL	President and CEO	2025-07-18	$1.47M
買入	BOUDREAUX GAIL	President and CEO	2025-07-18	$302K
賣出	Kaye Mark	EVP & CFO	2025-04-24	$1.95M

View all insider trades →

Form 144 Pre-Sale Notices

Filings (90d)

$839K

Total Est. Value

2K shares

Planned Shares

Last Filed 2026-07-07

Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
CLARK R KERRY	Director	2026-07-07	2K shares	$630K
Penczek Ronald W	Officer	2026-06-12	369 shares	$149K
Dixon Robert L JR	Director	2026-06-11	151 shares	$61K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-15

2026-07-15

On July 15, 2026, Elevance Health, Inc. issued a press release reporting its financial results for the second quarter ended June 30, 2026. The release is furnished under Item 2.02 and attached as Exhibit 99.1 to this 8-K filing.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ELEVANCE HEALTH INC (ELV)?

Major stakeholders currently include BlackRock, Inc. ($5.8B), Vanguard Capital Management LLC ($4.2B), State Street CORP ($3.0B). Based on the latest 13F filings, there are a total of 1466 tracked investment funds and institutions maintaining positions in ELV.

What is the overall institutional sentiment toward ELV recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $14.4B, driven by 606 managers accumulating shares while 859 reduced their exposure.

Which institutions have been selling or reducing their ELV positions?

In the latest period, 650 funds trimmed their holdings, and 209 managers completely exited their positions. The aggregate reported sell value was $38.0B.

Are there any notable investors adding ELV to their portfolios?

Yes, buying activity remains notable. 121 institutions opened new positions in {ticker}, and 485 existing holders added to their shares. The total reported buy value for the quarter amounted to $25.0B.